[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658706":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":37,"studyPopulation":11,"armGroups":38,"interventions":50,"overallOfficials":11,"centralContacts":57,"locations":68,"responsibleParty":87,"collaborators":89,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":11,"eligibilityCriteria":97,"healthyVolunteers":94,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":11,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":114,"whyStopped":11,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"The First Affiliated Hospital of Zhejiang Chinese Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Yale Global Tic Severity Scale Total Tic Score",null,"baseline (Week 0), during treatment (Week 4), and after treatment (Week 8), with a follow-up period of 4 weeks after the end of treatment (Week 12)",[14,17,20,23,25],{"measure":15,"description":11,"timeFrame":16},"Change in YGTSS-TTS score from baseline","week 4,week12",{"measure":18,"description":11,"timeFrame":19},"Change in YGTSS scores across other dimensions relative to baseline","week 4,week 8,week 12",{"measure":21,"description":11,"timeFrame":22},"Children's Yale-Brown Obsessive Compulsive Scale","Week 0, Week 4, Week 8, Week 12",{"measure":24,"description":11,"timeFrame":22},"Swanson, Nolan, and Pelham-IV-18",{"measure":26,"description":11,"timeFrame":22},"Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life",{"allocation":28,"interventionModel":29,"interventionModelDescription":11,"primaryPurpose":30,"observationalModel":11,"timePerspective":11,"maskingInfo":31},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":32,"maskingDescription":11,"whoMasked":33},"TRIPLE",[34,35,36],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR","Participants will be randomly assigned to receive transcutaneous auricular point electrical stimulation or micro-stimulation treatment. Both treatments will be administered 5 times per week, starting from the time of enrollment and lasting for 8 weeks. The study outcomes will be evaluated at four time points: baseline (Week 0), during treatment (Week 4), and after treatment (Week 8), with a follow-up period of 4 weeks after the end of treatment (Week 12).",[39,46],{"label":40,"type":41,"description":42,"interventionNames":43},"Transcutaneous Auricular Point Electrical Stimulation","EXPERIMENTAL","After skin disinfection, the connecting clip is fixed to the Auricular Point, an electroacupuncture apparatus will be connected. The stimulation parameters will be sparse and dense waves, 4\u002F20Hz (4Hz for 5 seconds, 20Hz for 10 seconds, alternating); the pulse width is 0.2ms ± 30%, and the current intensity will be adjusted according to the participant's comfort level.",[44,45],"Device: Transcutaneous Auricular Point Electrical Stimulation","Device: micro-stimulation",{"label":47,"type":48,"description":42,"interventionNames":49},"micro-stimulation","SHAM_COMPARATOR",[44,45],[51,55],{"type":52,"name":40,"description":53,"armGroupLabels":54,"otherNames":11},"DEVICE","Participants in the Transcutaneous Auricular Point Electrical Stimulation group will receive Transcutaneous Auricular Point Electrical Stimulation 5 a week, with each session lasting 30 minutes. The treatment will start from the time of enrollment and lasting for 8 weeks.",[40,47],{"type":52,"name":47,"description":53,"armGroupLabels":56,"otherNames":11},[40,47],[58,64],{"name":59,"role":60,"phone":61,"phoneExt":62,"email":63},"Simeng Wang, PHD","CONTACT","8618811022134","zhiyixiong@fox","18811022134@163.com",{"name":65,"role":60,"phone":66,"phoneExt":11,"email":67},"Zhiyi Xiong, PHD","8618811022104","zhiyixiong@foxmail.com",[69],{"facility":70,"status":11,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"The first Affiliated Hospital of Zhejiang Chinese Medical University (FirstZhejiangCMU)","Hangzhou","Zhejiang","310000","China","CN",{"type":77,"coordinates":78},"Point",[79,80],120.16142,30.29365,{"lat":80,"lon":79},[83,84,85],{"name":59,"role":60,"phone":61,"phoneExt":11,"email":63},{"name":65,"role":60,"phone":66,"phoneExt":11,"email":67},{"name":59,"role":86,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[90],{"name":91,"class":6},"Zhejiang Provincial Tongde Hospital","100658706","a-randomized-controlled-clinical-trial-of-transcutaneous-auricular-point-electrical-stimulation-for-improving-symptoms-of-chronic-tic-disorders-in-childrenadolescents-100658706",false,"NCT07854665","A Randomized Controlled Clinical Trial of Transcutaneous Auricular Point Electrical Stimulation for Improving Symptoms of Chronic Tic Disorders in Children\u002FAdolescents","Inclusion Criteria:\n\n（1）Meet DSM-5 diagnostic criteria for Tourette syndrome or persistent (chronic) motor or vocal tic disorder; (2) Age between 6 and 18 years, regardless of gender; (3) YGTSS-TTS score \\>15; for participants with only motor or vocal tics, a YGTSS-TTS score \\>10 is required; (4) If currently on medication, the dosage of tic-related medications must have been stable for the past 4 weeks, and no changes to medication are planned during the study period; (5) No physical therapy or surgical treatment for this condition within the past 8 weeks; (6) The participant's guardian signs an informed consent form, and participants aged 8 years and older sign an appropriate assent document, voluntarily agreeing to participate in the study.\n\nExclusion Criteria:\n\n(1) Presence of severe mental disorders, such as schizophrenia, bipolar disorder, severe depression, suicide risk, etc., or severe cognitive dysfunction, making it impossible to cooperate with the study; (2) Skin damage, infection, eczema, etc. in the ear area, making treatment impossible; (3) Implanted with cardiac pacemaker, implantable nerve stimulator or other electronic implant devices; (4) Complicated with severe cardiovascular or other important organ diseases; (5) Currently participating in other clinical studies.","ALL","6 Years","18 Years",{"count":102,"type":103},124,"ESTIMATED","INTERVENTIONAL",[106],"NA","The objective of this trial is to evaluate the effect of transcutaneous auricular point electrical stimulation compared to the micro-stimulation in the treatment of chronic tic disorder in adolescents",[109],"Tic Disorder",[109,40,111,112,113],"Transcutaneous Auricular Vagus Nerve Stimulation","Randomized Controlled Trial","Placebo","NOT_YET_RECRUITING","2026-09-27",{"date":117,"type":118},"2026-10-02","ACTUAL",{"date":120,"type":103},"2026-10-31",{"date":122,"type":103},"2027-09-30",{"name":5,"class":6},1]